Renese - Pfizer Labs

Manufacturer
Pfizer Labs
Effective date
2005-12-14
Label type
HUMAN PRESCRIPTION DRUG LABELING
Version
1
Source
full-release
Hydrated at
2026-05-31 20:06:38

Label at a glance#

ProductRenese
Label structure10 sections

Dosage and administration

Therapy should be individualized according to patient response. This therapy should be titrated to gain maximal therapeutic response as well as the minimal dose possible to maintain that therapeutic response. The usual dosage of Renese tablets for diuretic therapy is 1 to 4 mg daily, and for antihypertensive therapy is 2 to 4 mg daily.

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Renese® is designated generically as polythiazide, and chemically as 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-2-methyl-3-[[(2,2,2-trifluoroethyl)thio]methyl]-, 1,1-dioxide. It is a white crystalline substance, insoluble in water but readily soluble in alkaline solution.

Inert Ingredients: dibasic calcium phosphate; lactose; magnesium stearate; polyethylene glycol; sodium lauryl sulfate; starch; vanillin. The 2 mg tablets also contain: Yellow 6; Yellow 10.

ACTION

SPL UNCLASSIFIED SECTION

The mechanism of action results in an interference with the renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosage all thiazides are approximately equal in their diuretic potency. The mechanism whereby thiazides function in the control of hypertension is unknown.

INDICATIONS

INDICATIONS & USAGE SECTION

Renese is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy.

Renese has also been found useful in edema due to various forms of renal dysfunction as: Nephrotic syndrome; Acute glomerulonephritis; and Chronic renal failure.

Renese is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.

Usage in Pregnancy

SPL UNCLASSIFIED SECTION

The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia.

Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Thiazides are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy (however, see Warnings, below). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Anuria. Hypersensitivity to this or other sulfonamide derived drugs.

WARNINGS

WARNINGS SECTION

Thiazides should be used with caution in severe renal disease. In patients with renal disease, thiazides may precipitate azotemia. Cumulative effects of the drug may develop in patients with impaired renal function.

Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma.

Thiazides may add to or potentiate the action of other antihypertensive drugs. Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs.

Sensitivity reactions may occur in patients with a history of allergy or bronchial asthma.

The possibility of exacerbation or activation of systemic lupus erythematosus has been reported.

Usage in Pregnancy

SPL UNCLASSIFIED SECTION

Thiazides cross the placental barrier and appear in cord blood. The use of thiazides in pregnant women requires that the anticipated benefit be weighed against possible hazards to the fetus. These hazards include fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions which have occurred in the adult.

Nursing Mothers

SPL UNCLASSIFIED SECTION

Thiazides appear in breast milk. If use of the drug is deemed essential, the patient should stop nursing.

PRECAUTIONS

PRECAUTIONS SECTION

Periodic determination of serum electrolytes to detect possible electrolyte imbalance should be performed at appropriate intervals.

All patients receiving thiazide therapy should be observed for clinical signs of fluid or electrolyte imbalance; namely, hyponatremia, hypochloremic alkalosis, and hypokalemia. Serum and urine electrolyte determinations are particularly important when the patient is vomiting excessively or receiving parenteral fluids. Medication such as digitalis may also influence serum electrolytes. Warning signs, irrespective of cause, are: dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea and vomiting.

Hypokalemia may develop with thiazides as with any other potent diuretic, especially with brisk diuresis, when severe cirrhosis is present, or during concomitant use of corticosteroids or ACTH.

Interference with adequate oral electrolyte intake will also contribute to hypokalemia. Digitalis therapy may exaggerate metabolic effects of hypokalemia especially with reference to myocardial activity.

Any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (as in liver disease or renal disease). Dilutional hyponatremia may occur in edematous patients in hot weather; appropriate therapy is water restriction, rather than administration of salt except in rare instances when the hyponatremia is life threatening. In actual salt depletion, appropriate replacement is the therapy of choice.

Hyperuricemia may occur or frank gout may be precipitated in certain patients receiving thiazide therapy.

Insulin requirements in diabetic patients may be increased, decreased, or unchanged. Latent diabetes mellitus may become manifest during thiazide administration.

Thiazide drugs may increase the responsiveness to tubocurarine.

The antihypertensive effects of the drug may be enhanced in the postsympathectomy patient.

Thiazides may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.

If progressive renal impairment becomes evident, as indicated by a rising nonprotein nitrogen or blood urea nitrogen, a careful reappraisal of therapy is necessary with consideration given to withholding or discontinuing diuretic therapy.

Thiazides may decrease serum PBI levels without signs of thyroid disturbance.

Pediatric Use

SPL UNCLASSIFIED SECTION

Safety and effectiveness in pediatric patients have not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

A. GASTROINTESTINAL SYSTEM REACTIONS

SPL UNCLASSIFIED SECTION

  1. anorexia
  2. gastric irritation
  3. nausea
  4. vomiting
  5. cramping
  6. diarrhea
  7. constipation
  8. jaundice (intrahepatic cholestatic jaundice)
  9. pancreatitis

B. CENTRAL NERVOUS SYSTEM REACTIONS

SPL UNCLASSIFIED SECTION

  1. dizziness
  2. vertigo
  3. paresthesias
  4. headache
  5. xanthopsia

C. HEMATOLOGIC REACTIONS

SPL UNCLASSIFIED SECTION

  1. leukopenia
  2. agranulocytosis
  3. thrombocytopenia
  4. aplastic anemia

D. DERMATOLOGIC—HYPERSENSITIVITY REACTIONS

SPL UNCLASSIFIED SECTION

  1. purpura
  2. photosensitivity
  3. rash
  4. urticaria
  5. necrotizing angiitis

    (vasculitis)

    (cutaneous vasculitis)

E. CARDIOVASCULAR REACTION

SPL UNCLASSIFIED SECTION

Orthostatic hypotension may occur and may be aggravated by alcohol, barbiturates or narcotics.

F. OTHER

SPL UNCLASSIFIED SECTION

  1. hyperglycemia
  2. glycosuria
  3. hyperuricemia
  4. muscle spasm
  5. weakness
  6. restlessness

Whenever adverse reactions are moderate or severe, thiazide dosage should be reduced or therapy withdrawn.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Therapy should be individualized according to patient response. This therapy should be titrated to gain maximal therapeutic response as well as the minimal dose possible to maintain that therapeutic response. The usual dosage of Renese tablets for diuretic therapy is 1 to 4 mg daily, and for antihypertensive therapy is 2 to 4 mg daily.

HOW SUPPLIED

HOW SUPPLIED SECTION

RENESE (polythiazide) Tablets are available as:

1 mg white, scored tablets in bottles of 100 (NDC 0069-3750-66).

2 mg yellow, scored tablets in bottles of 100 (NDC 0069-3760-66).

4 mg white, scored tablets in bottles of 100 (NDC 0069-3770-66).

SPL UNCLASSIFIED SECTION

Rx Only

SPL UNCLASSIFIED SECTION
SPL UNCLASSIFIED SECTION

69-1116-00-6

April 1997

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
198110polythiazide 1 MG Oral TabletPSN1
198111polythiazide 2 MG Oral TabletPSN1
198112polythiazide 4 MG Oral TabletPSN1
208716Renese 1 MG Oral TabletPSN1
208717Renese 2 MG Oral TabletPSN1
208719Renese 4 MG Oral TabletPSN1
208716polythiazide 1 MG Oral Tablet [Renese]SBD1
208717polythiazide 2 MG Oral Tablet [Renese]SBD1
208719polythiazide 4 MG Oral Tablet [Renese]SBD1
198110polythiazide 1 MG Oral TabletSCD1
198111polythiazide 2 MG Oral TabletSCD1
198112polythiazide 4 MG Oral TabletSCD1
208716Renese 1 MG Oral TabletSY1
208717Renese 2 MG Oral TabletSY1
208719Renese 4 MG Oral TabletSY1

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
0069-3750-66Renese100 in BOTTLETABLET1001
0069-3760-66Renese100 in BOTTLETABLET1001
0069-3770-66Renese100 in BOTTLETABLET1001

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
0069-3750RENESE (POLYTHIAZIDE) TABLET [PFIZER LABS]11 package rows20060131_ABD6ECF0-DC8E-41DE-89F2-1E36ED9D6535.zip
0069-3760RENESE (POLYTHIAZIDE) TABLET [PFIZER LABS]11 package rows20060131_ABD6ECF0-DC8E-41DE-89F2-1E36ED9D6535.zip
0069-3770RENESE (POLYTHIAZIDE) TABLET [PFIZER LABS]11 package rows20060131_ABD6ECF0-DC8E-41DE-89F2-1E36ED9D6535.zip

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
polythiazideACTIVE INGREDIENT36780APV5N1
polythiazideACTIVE MOIETY36780APV5N1
dibasic calcium phosphateINACTIVE INGREDIENT1
lactoseINACTIVE INGREDIENT1
magnesium stearateINACTIVE INGREDIENT1
polyethylene glycolINACTIVE INGREDIENT1
sodium lauryl sulfateINACTIVE INGREDIENT1
starchINACTIVE INGREDIENT1
vanillinINACTIVE INGREDIENT1
yellow 10INACTIVE INGREDIENT1
yellow 6INACTIVE INGREDIENT1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 11 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0069-37500069-3750-66
0069-37600069-3760-66
0069-37700069-3770-66

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 3 · 154 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
magnesium stearateMAGNESIUM STEARATE70097M6I30GRANULE, FOR SUSPENSION / ORAL14 mgName fallback — name candidate
39 equally ranked IID candidates
magnesium stearateMAGNESIUM STEARATE70097M6I30TABLET, ORALLY DISINTEGRATING / ORAL187 mgName fallback — name candidate
39 equally ranked IID candidates
starchSTARCHTABLET, DELAYED RELEASE / ORAL232 mgName fallback — name candidate
22 equally ranked IID candidates
lactoseLACTOSEJ2B2A4N98GCAPSULE, COATED, EXTENDED RELEASE / ORALNAName fallback — name candidate
36 equally ranked IID candidates
sodium lauryl sulfateSODIUM LAURYL SULFATE368GB5141JTABLET, CHEWABLE / ORAL6 mgName fallback — name candidate
42 equally ranked IID candidates
magnesium stearateMAGNESIUM STEARATE70097M6I30TABLET, SUGAR COATED / ORALNAName fallback — name candidate
39 equally ranked IID candidates
sodium lauryl sulfateSODIUM LAURYL SULFATE368GB5141JPASTE / DENTAL1.5 %w/wName fallback — name candidate
42 equally ranked IID candidates
sodium lauryl sulfateSODIUM LAURYL SULFATE368GB5141JCAPSULE, COATED, EXTENDED RELEASE / ORALNAName fallback — name candidate
42 equally ranked IID candidates
sodium lauryl sulfateSODIUM LAURYL SULFATE368GB5141JOINTMENT / TOPICAL14 mgName fallback — name candidate
42 equally ranked IID candidates
magnesium stearateMAGNESIUM STEARATE70097M6I30TABLET / SUBLINGUAL17.5 mgName fallback — name candidate
39 equally ranked IID candidates
lactoseLACTOSEJ2B2A4N98GPOWDER / RESPIRATORY (INHALATION)90 mgName fallback — name candidate
36 equally ranked IID candidates
sodium lauryl sulfateSODIUM LAURYL SULFATE368GB5141JTABLET, CHEWABLE, EXTENDED RELEASE / ORAL1 mgName fallback — name candidate
42 equally ranked IID candidates
lactoseLACTOSEJ2B2A4N98GTABLET, CHEWABLE / ORAL1412 mgName fallback — name candidate
36 equally ranked IID candidates
lactoseLACTOSEJ2B2A4N98GPOWDER / VAGINAL430 mgName fallback — name candidate
36 equally ranked IID candidates
vanillinVANILLINCHI530446XSUSPENSION / ORAL6 mgName fallback — name candidate
15 equally ranked IID candidates
sodium lauryl sulfateSODIUM LAURYL SULFATE368GB5141JCAPSULE, COATED PELLETS / ORAL1 mgName fallback — name candidate
42 equally ranked IID candidates
starchSTARCHTABLET / ORAL2440 mgName fallback — name candidate
22 equally ranked IID candidates
lactoseLACTOSEJ2B2A4N98GCREAM / VAGINAL3 %w/wName fallback — name candidate
36 equally ranked IID candidates
starchSTARCHTABLET / RECTAL55 mgName fallback — name candidate
22 equally ranked IID candidates
starchSTARCHTABLET, CHEWABLE / ORAL309 mgName fallback — name candidate
22 equally ranked IID candidates
lactoseLACTOSEJ2B2A4N98GTABLET / RECTAL20 mgName fallback — name candidate
36 equally ranked IID candidates
sodium lauryl sulfateSODIUM LAURYL SULFATE368GB5141JCREAM / TOPICAL214 mgName fallback — name candidate
42 equally ranked IID candidates
magnesium stearateMAGNESIUM STEARATE70097M6I30TABLET, CHEWABLE / ORAL127 mgName fallback — name candidate
39 equally ranked IID candidates
starchSTARCHTABLET / BUCCAL45 mgName fallback — name candidate
22 equally ranked IID candidates
lactoseLACTOSEJ2B2A4N98GTABLET / ORAL2500 mgName fallback — name candidate
36 equally ranked IID candidates
sodium lauryl sulfateSODIUM LAURYL SULFATE368GB5141JTABLET, DELAYED RELEASE / ORAL199 mgName fallback — name candidate
42 equally ranked IID candidates
lactoseLACTOSEJ2B2A4N98GTABLET, DELAYED RELEASE / ORAL160 mgName fallback — name candidate
36 equally ranked IID candidates
lactoseLACTOSEJ2B2A4N98GINJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR133 mgName fallback — name candidate
36 equally ranked IID candidates
sodium lauryl sulfateSODIUM LAURYL SULFATE368GB5141JCAPSULE, EXTENDED RELEASE / ORAL166 mgName fallback — name candidate
42 equally ranked IID candidates
lactoseLACTOSEJ2B2A4N98GINJECTION, SOLUTION / INTRAVENOUS0.45 %w/vName fallback — name candidate
36 equally ranked IID candidates
magnesium stearateMAGNESIUM STEARATE70097M6I30DROPS / ORALNAName fallback — name candidate
39 equally ranked IID candidates
lactoseLACTOSEJ2B2A4N98GCAPSULE, EXTENDED RELEASE / ORAL120 mgName fallback — name candidate
36 equally ranked IID candidates
vanillinVANILLINCHI530446XTABLET, ORALLY DISINTEGRATING / ORAL0.26 mgName fallback — name candidate
15 equally ranked IID candidates
vanillinVANILLINCHI530446XTABLET, FILM COATED, EXTENDED RELEASE / ORAL1 mgName fallback — name candidate
15 equally ranked IID candidates
magnesium stearateMAGNESIUM STEARATE70097M6I30GRANULE / ORAL629 mgName fallback — name candidate
39 equally ranked IID candidates
magnesium stearateMAGNESIUM STEARATE70097M6I30POWDER / TOPICAL104 mgName fallback — name candidate
39 equally ranked IID candidates
sodium lauryl sulfateSODIUM LAURYL SULFATE368GB5141JTABLET / SUBLINGUAL1.1 mgName fallback — name candidate
42 equally ranked IID candidates
sodium lauryl sulfateSODIUM LAURYL SULFATE368GB5141JINSERT / VAGINAL15 mgName fallback — name candidate
42 equally ranked IID candidates
vanillinVANILLINCHI530446XELIXIR / ORALNAName fallback — name candidate
15 equally ranked IID candidates
starchSTARCHTABLET, EXTENDED RELEASE / ORAL130.45 mgName fallback — name candidate
22 equally ranked IID candidates
sodium lauryl sulfateSODIUM LAURYL SULFATE368GB5141JTABLET, FOR SUSPENSION / ORAL264 mgName fallback — name candidate
42 equally ranked IID candidates
starchSTARCHCAPSULE, COATED PELLETS / ORAL36.4 mgName fallback — name candidate
22 equally ranked IID candidates
sodium lauryl sulfateSODIUM LAURYL SULFATE368GB5141JTABLET / BUCCAL5.18 mgName fallback — name candidate
42 equally ranked IID candidates
starchSTARCHCREAM / TOPICALNAName fallback — name candidate
22 equally ranked IID candidates
lactoseLACTOSEJ2B2A4N98GINJECTION / INTRAMUSCULAR203.5 mgName fallback — name candidate
36 equally ranked IID candidates
sodium lauryl sulfateSODIUM LAURYL SULFATE368GB5141JCAPSULE / RESPIRATORY (INHALATION)NAName fallback — name candidate
42 equally ranked IID candidates
sodium lauryl sulfateSODIUM LAURYL SULFATE368GB5141JGRANULE / ORAL12 mgName fallback — name candidate
42 equally ranked IID candidates
sodium lauryl sulfateSODIUM LAURYL SULFATE368GB5141JSPRAY / TOPICAL7 mgName fallback — name candidate
42 equally ranked IID candidates
magnesium stearateMAGNESIUM STEARATE70097M6I30RING / VAGINAL2 mgName fallback — name candidate
39 equally ranked IID candidates
lactoseLACTOSEJ2B2A4N98GCAPSULE, DELAYED RELEASE / ORAL231.84 mgName fallback — name candidate
36 equally ranked IID candidates
lactoseLACTOSEJ2B2A4N98GPOWDER, FOR SOLUTION / ORALNAName fallback — name candidate
36 equally ranked IID candidates
magnesium stearateMAGNESIUM STEARATE70097M6I30INSERT / VAGINAL69 mgName fallback — name candidate
39 equally ranked IID candidates
magnesium stearateMAGNESIUM STEARATE70097M6I30TABLET, CHEWABLE, EXTENDED RELEASE / ORAL9 mgName fallback — name candidate
39 equally ranked IID candidates
magnesium stearateMAGNESIUM STEARATE70097M6I30TABLET, COATED / ORAL184 mgName fallback — name candidate
39 equally ranked IID candidates
lactoseLACTOSEJ2B2A4N98GINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVITARY193.8 mgName fallback — name candidate
36 equally ranked IID candidates
vanillinVANILLINCHI530446XTABLET, FILM COATED / ORAL5 mgName fallback — name candidate
15 equally ranked IID candidates
lactoseLACTOSEJ2B2A4N98GTABLET / BUCCAL296.7 mgName fallback — name candidate
36 equally ranked IID candidates
sodium lauryl sulfateSODIUM LAURYL SULFATE368GB5141JCAPSULE, DELAYED RELEASE / ORAL46 mgName fallback — name candidate
42 equally ranked IID candidates
starchSTARCHTABLET, FILM COATED / ORAL480 mgName fallback — name candidate
22 equally ranked IID candidates
lactoseLACTOSEJ2B2A4N98GFILM, EXTENDED RELEASE / TRANSDERMAL675 mgName fallback — name candidate
36 equally ranked IID candidates

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
ABD6ECF0-DC8E-41DE-89F2-1E36ED9D6535ABD6ECF0-DC8E-41DE-89F2-1E36ED9D65352005-12-14Warnings, Adverse reactionsExact identifier
spl id: ABD6ECF0-DC8E-41DE-89F2-1E36ED9D6535
spl set id: ABD6ECF0-DC8E-41DE-89F2-1E36ED9D6535

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.